Chapter 27 Review Questions Flashcards Preview

P & P II > Chapter 27 Review Questions > Flashcards

Flashcards in Chapter 27 Review Questions Deck (10)
Loading flashcards...
1

The incidence rate of bone cancer is highest during what period?
a. Infancy
b. Adulthood
c. Adolescence
d. Equal for all age

c. Adolescence

2

A nonosseous malignant tumor of the marrow is a(an):
a. fibrosarcoma.
b. chondrosarcoma.
c. osteosarcoma.
d. multiple myeloma

d. multiple myeloma

3

A bone lesion that results from primary sites elsewhere in the body is a(n):
a. osteosarcoma.
b. multiple myeloma.
c. metastatic tumor.
d. chondrosarcoma.

c. metastatic tumor.

4

The most common site of a primary bone sarcoma is:
a. epiphyseal.
b. metaphyseal.
c. diaphyseal.
d. shaft.

a. epiphyseal.

5

Prognostic indicators for patients with primary bone cancer include all of the following except:
a. age.
b. gender.
c. location.
d. weight

b. gender.

6

The most common site of metastasis from primary bone cancer is:
a. brain.
b. bowel.
c. lung.
d. distal extremities

c. lung.

7

_________________ is most commonly used in treating metastatic bone disease that results from primary prostate or breast cancer.
a. Technetium-99m
b. Iodine-131m
c. Strontium-89m
d. Iodine-125m

c. Strontium-89m

8

Although the exact cause of STS is unknown, a factor that has been implicated is:
a. prior sun exposure.
b. appearance as a second primary 5 to 15 years after high-dose radiation therapy for other cancers.
c. predisposition of Paget’s disease.
d. tobacco use

b. appearance as a second primary 5 to 15 years after high-dose radiation therapy for other cancers.

9

Factors or clinical signs that are incorporated in the staging systems and considered appropriate as general prognostic indicators for STS include:
I. histology.
II. size.
III. gender.
a. I and II
b. I and III
c. II and III
d. I, II, and III

a. I and II

10

Regional lymph nodes are generally not included in the treatment portals for STS. Which of the following are exceptions for this statement?
I. Rhabdomyosarcoma
II. Synovial sarcoma
III. Leiomyosarcoma
a. I and II
b. I and III
c. II and III
d. I, II, and III

a. I and II